Journal article icon

Journal article

CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action

Abstract:

CD6 is a type I T cell surface receptor which modulates antigen receptor signalling. Its activity is regulated by binding of its membrane proximal domain (domain 3) to a cell surface ligand, CD166. CD6 monoclonal antibodies (mAbs) specific for the membrane distal domain (domain 1) perturb CD6 function including itolizumab (Alzumab™) which has reached the clinic for treatment of autoimmune disease. We characterised molecular and functional properties of several CD6 mAbs including itolizumab to...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1111/imm.12952

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Pathology Dunn School
Hartland, A More by this author
Breuning, J More by this author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Pathology Dunn School
Publisher:
John Wiley & Sons Ltd Publisher's website
Journal:
Immunology Journal website
Volume:
155
Issue:
2
Pages:
273-282
Publication date:
2018-06-13
Acceptance date:
2018-05-11
DOI:
EISSN:
1365-2567
ISSN:
0019-2805
Pubs id:
pubs:852265
URN:
uri:cb871e93-af75-44af-8331-ebad49db76e0
UUID:
uuid:cb871e93-af75-44af-8331-ebad49db76e0
Local pid:
pubs:852265

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP